Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

    Not recruiting

    2 1 1 1
    France Italy Poland Spain
  • Study of Venetoclax and Azacitidine for Patients with Acute Myeloid Leukemia After Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia France Germany Greece Hungary Italy +1
  • Study of Venetoclax and Azacitidine for Adults 18+ with Acute Myeloid Leukemia Not Eligible for Standard Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany
  • Study on the Effectiveness of Imetelstat for Patients with High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia After HMA Treatment Failure

    Not recruiting

    2 1 1 1
    France Germany
  • Study on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Study of Magrolimab and Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Germany
  • Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Belgium The Netherlands
  • Study Comparing Pevonedistat, Venetoclax, and Azacitidine with Venetoclax and Azacitidine in Adults with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

    Not recruiting

    2 1 1 1
    Italy Poland
  • Study on Decitabine and Drug Combination for Elderly Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

    Not recruiting

    2 1 1 1
    Norway
  • Study on Venetoclax, Cytarabine, and Mitoxantrone for Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML) Eligible for Intensive Treatment

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Germany